What is Phable?
Phable operates at the intersection of mobile technology and clinical care, providing a comprehensive ecosystem for the management of lifestyle-related chronic conditions. The platform distinguishes itself by integrating 24x7 doctor intervention with an intelligent care companion, effectively bridging the gap between patient monitoring and proactive medical guidance. By digitizing the patient journey, Phable addresses critical inefficiencies in traditional healthcare delivery, positioning itself as a leader in the rapidly evolving digital health landscape. Its market position is reinforced by a focus on scalability and high-touch patient engagement, which are essential for long-term success in the enterprise-level healthtech market.
How much funding has Phable raised?
Phable has raised a total of $40.1M across 4 funding rounds:
Angel/Seed
$150K
Other Financing Round
$1M
Series A
$14M
Series B
$25M
Angel/Seed (2019): $150K with participation from SOSV
Other Financing Round (2020): $1M led by Inflection Point Ventures
Series A (2021): $14M supported by SOSV LLC, Omron Ventures, and Manipal Hospitals
Series B (2022): $25M featuring Aflac Ventures, Stride Ventures, Kalaari Capital, and Digital Horizon
Key Investors in Phable
SOSV
SOSV is a multi-stage venture capital investor that provides intellectual and financial capital to accelerate founders big ideas.
Inflection Point Ventures
IPV Inflection Point Ventures is India's leading angel investing platform focused on providing viable investment opportunities for investors while being founder-friendly.
Kalaari Capital
Kalaari Capital is a venture capital firm focused on investing in early-stage technology companies in India, providing both capital and strategic guidance.
What's next for Phable?
With the successful closure of this Series B financing, Phable is poised to enter a phase of aggressive market expansion and product refinement. The strategic focus will likely shift toward deepening its clinical integration, expanding its network of healthcare providers, and enhancing the predictive capabilities of its intelligent care companion. As the company scales, it will need to navigate the complexities of the healthcare regulatory environment while maintaining the high standard of care that has attracted significant institutional backing. The infusion of capital serves as a catalyst for Phable to solidify its footprint in the competitive healthtech arena, potentially setting the stage for future market leadership and sustained operational growth.
See full Phable company page
